| Budget Amount *help |
¥18,070,000 (Direct Cost: ¥13,900,000、Indirect Cost: ¥4,170,000)
Fiscal Year 2019: ¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000)
Fiscal Year 2018: ¥6,110,000 (Direct Cost: ¥4,700,000、Indirect Cost: ¥1,410,000)
Fiscal Year 2017: ¥6,760,000 (Direct Cost: ¥5,200,000、Indirect Cost: ¥1,560,000)
|
|---|
| Outline of Final Research Achievements |
In this study, we obtained new insights: small-sized lipid nanoparticles showing excellent transability to the lymph node; negative charged lipid nanoparticles that are efficiently taken up by T cells in the lymph node; siRNA-loaded lipid nanoparticles showing effective gene silencing of IDO1, inhibitory gene, in dendritic cells; a strategy for reducing cytotoxicity of siRNA-loaded lipid nanoparticles in immune cells. In particular, we first reported the delivery to lymph node with lipid nanoparticles prepared by microfluidic devices. These findings should provide useful insights for the development of cancer immunotherapy based on lipid nanoparticles targeting lymph nodes.
|
